ANX

[phabrux]

About the news from today, It looks like ANX need more cash!  Saying that, I am not sure how to read it exactly.  Are we talking about dillution(like printing more shares) or is it just ANX intention's of selling a few shares(15,495,867) from they own reserve, which would allready be accounted in the last oustanding Shares figure?

Thanks to anybody who could gives me a  answer!





SAN DIEGO, May 16, 2006 /PRNewswire-FirstCall via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (ANX) today announced that it plans to publicly offer 15,495,867 shares of its common stock in a firm commitment underwritten offering pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, ADVENTRX plans to grant to the underwriters a 30-day option to purchase up to an additional 2,324,380 shares of common stock to cover over-allotments, if any. All of the shares are being sold by ADVENTRX. UBS Investment Bank is the sole book-running manager in this offering. CIBC World Markets Corp. and RBC Capital Markets are acting as co-lead managers, and Fortis Securities LLC is acting as co-manager.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus may be obtained from UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171 or by phone at 212-821-3000.

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance


SAN DIEGO, May 16, 2006 /PRNewswire-FirstCall via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (ANX) today announced that it plans to publicly offer 15,495,867 shares of its common stock in a firm commitment underwritten offering pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, ADVENTRX plans to grant to the underwriters a 30-day option to purchase up to an additional 2,324,380 shares of common stock to cover over-allotments, if any. All of the shares are being sold by ADVENTRX. UBS Investment Bank is the sole book-running manager in this offering. CIBC World Markets Corp. and RBC Capital Markets are acting as co-lead managers, and Fortis Securities LLC is acting as co-manager.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus may be obtained from UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171 or by phone at 212-821-3000.

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance

[njshiva]

Whats going on here.. .....news ahead??

[phabrux]

ANX left a 10 months descending wedge for finally engaging into a ascending channel.

"ADVENTRX has expanded its product candidate portfolio substantially over the past year and is rapidly advancing its product candidates into the clinic," stated Evan M. Levine, chief executive officer of ADVENTRX. "Depending on preclinical results and anticipated discussions with the FDA, we may have up to five product candidates in clinical development by the end of the year. In the interim, we look forward to announcing results of our 300- patient Phase 2b clinical trial of CoFactor for the treatment of metastatic colorectal cancer and results from our marketing-enabling study of ANX-530 later this year."

Monday May 7 ADVENTRX's announced financial results for the three months ended March 31, 2007
In line with Analyst Estimates:
Q1 2007   pps(fully diluted): (0.06)   Versus   Q1 2006   pps(fully diluted): (0.06)